尋常性天疱瘡（PV）市場 - 市場の洞察、疫学、市場予測：2034年

尋常性天疱瘡（PV）は、口や喉、時には生殖器などの皮膚や粘膜に痛みを伴う水疱やびらんを認める重篤で稀な自己免疫疾患です。この疾患は、表皮の細胞接着に不可欠なタンパク質であるデスモグレインを免疫系が誤って攻撃することにより発症し、細胞の剥離と水疱形成を引き起こします。

天疱瘡に伴う水疱は一般的に弛緩性で壊れやすく、主に頭皮、顔面、胸部、背部などの部位、特に口などの粘膜に形成されます。容易に破裂し、しばしば痛みを伴う開放性のただれを生じ、治癒に時間がかかります。より深い皮膚層を侵し、より強固で弾力性のある水疱を生じる天疱瘡とは異なり、天疱瘡はより表在性の皮膚層を侵し、繊細で容易に破裂する水疱を生じます。

尋常性天疱瘡の診断には、生検および抗体検査、特に抗デスモグレイン抗体の同定による、水疱性類天疱瘡や他のタイプの天疱瘡などの他の水疱形成性疾患との鑑別を行います。

治療は、主に副腎皮質ステロイド、アザチオプリンやミコフェノラートなどの免疫抑制剤、自己抗体産生を担うB細胞を標的とするリツキシマブ別生物学的療法によって、水疱形成を引き起こす自己免疫活性を制御することに重点を置いています。現在、リツキサン（リツキシマブ）は尋常性天疱瘡の治療で唯一FDAに承認されている治療法であり、特に中等度から重度の症例で寛解を達成するための効果的な選択肢となっており、多くの場合、コルチコステロイドの投与量を少なくすることが可能です。

その他の支持療法としては、感染予防のための抗生物質投与、口腔内病変の疼痛管理、治癒を助けるための適切な創傷ケアなどがあります。再発の傾向があるにもかかわらず、綿密なモニタリングとこれらの治療により、多くの患者がPVを管理することができます。

主要7ヶ国における尋常性天疱瘡の市場規模では、米国が最も高い市場シェア、すなわち2023年には75％以上を占め、次いでドイツが続きます。EU4ヶ国と英国の中では、ドイツが2023年の市場規模のほぼ25%を占めています。米国は2023年に約2億5,000万米ドルでした。利用可能な治療法の中で、リツキシマブはPV市場を一変させた薬剤とみられています。

当レポートでは、主要7ヶ国における尋常性天疱瘡（PV）市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2034年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 尋常性天疱瘡（PV）市場概要

第4章 調査手法

第5章 エグゼクティブサマリー

第6章 重要な出来事

第7章 疾患の背景と概要

• イントロダクション
• 兆候と症状
• 病因
• 病態生理学
• リスク要因
• 診断
• 診断アルゴリズム
• 診断ガイドライン

第8章 治療と管理

• 治療アルゴリズム
• 治療ガイドライン

第9章 疫学と患者人口

• 主な調査結果
• 仮定と根拠
• 主要7ヶ国におけるPVの診断済み有病者総数
• 主要7ヶ国におけるPV治療症例総数
• 米国
• EU4ヶ国と英国
• 日本疫学

第10章 患者動向

第11章 新たな治療法

第12章 市場分析

• 主な調査結果
• 市場見通し
• 主要7ヶ国におけるPV市場規模
• 主要7ヶ国におけるPV治療薬別市場規模
• 米国における市場規模
• EU4ヶ国と英国における市場規模
• 日本における市場規模

第13章 KOLの見解

第14章 SWOT分析

第15章 アンメットニーズ

第16章 付録

第17章 DelveInsightのサービス内容

第18章 免責事項

List of Tables

• Table 1: Summary of Pemphigus Vulgaris Market and Epidemiology (2020-2034)
• Table 2: Total Diagnosed Prevalent Cases of PV in 7MM (2020-2034)
• Table 3: Total Treated Cases of PV in the 7MM (2020-2034)
• Table 4: Total Diagnosed Prevalent Cases of PV in the United States (2020-2034)
• Table 5: Gender-specific Cases of PV in the United States (2020-2034)
• Table 6: Age group-specific Cases of PV in the United States (2020-2034)
• Table 7: Severity-specific Cases of PV in the United States (2020-2034)
• Table 8: Total Treated Cases of PV in the United States (2020-2034)
• Table 9: Total Diagnosed Prevalent Cases of PV in EU4 and the UK (2020-2034)
• Table 10: Gender-specific cases of PV in EU4 and the UK (2020-2034)
• Table 11: Age group-specific Cases of PV in EU4 and the UK (2020-2034)
• Table 12: Severity-specific Cases of PV in EU4 and the UK (2020-2034)
• Table 13: Total Treated Cases of PV in EU4 and the UK (2020-2034)
• Table 14: Total Diagnosed Prevalent Cases of PV in Japan (2020-2034)
• Table 15: Gender-specific Cases of PV in Japan (2020-2034)
• Table 16: Age group-specific Cases of PV in Japan (2020-2034)
• Table 17: Severity-specific Cases of PV in Japan (2020-2034)
• Table 18: Total Treated Cases of PV in Japan (2020-2034)
• Table 19: CABA-201 (4-1BB CD19-CAR T), Clinical Trial Description, 2024
• Table 20: Total Market Size of PV in the 7MM in USD Million (2020-2034)
• Table 21: Market Size of PV by Therapies in the 7MM in USD Million (2020-2034)
• Table 22: Total Market Size of PV in the United States in USD Million (2020-2034)
• Table 23: Market Size of PV by Therapies in the United States in USD Million (2020-2034)
• Table 24: Total Market Size of PV in EU4 and the UK in USD Million (2020-2034)
• Table 25: Market Size of PV by Therapies in EU4 and the UK in USD Million (2020-2034)
• Table 26: Total Market Size of PV in Japan in USD Million (2020-2034)
• Table 27: Market Size of PV by Therapies in Japan in USD Million (2020-2034)

List of Figures

• Figure 1: Patients Suffering From PV
• Figure 2: Progression of PV and Associated Symptoms
• Figure 3: Comparison of Intraepidermal and Subepidermal Blistering Disorders
• Figure 4: Pathophysiology of Pemphigus
• Figure 5: Diagnostic Algorithm of PV
• Figure 6: Treatment Algorithm for mild PV
• Figure 7: Treatment algorithm for moderate and severe pemphigus vulgaris
• Figure 8: Total Diagnosed Prevalent Cases of PV in 7MM (2020-2034)
• Figure 9: Total Treated Cases of PV in the 7MM (2020-2034)
• Figure 10: Total Diagnosed Prevalent Cases of PV in the United States (2020-2034)
• Figure 11: Gender-specific cases of PV in the United States (2020-2034)
• Figure 12: Age group-specific Cases of PV in the United States (2020-2034)
• Figure 13: Severity-specific Cases of PV in the United States (2020-2034)
• Figure 14: Total Treated Cases of PV in the United States (2020-2034)
• Figure 15: Total Diagnosed Prevalent Cases of PV in EU4 and the UK (2020-2034)
• Figure 16: Gender-specific Cases of PV in EU4 and the UK (2020-2034)
• Figure 17: Age group-specific Cases of PV in EU4 and the UK (2020-2034)
• Figure 18: Severity-specific Cases of PV in EU4 and the UK (2020-2034)
• Figure 19: Total Treated Cases of PV in EU4 and the UK (2020-2034)
• Figure 20: Total Diagnosed Prevalent Cases of PV in Japan (2020-2034)
• Figure 21: Gender-specific cases of PV in Japan (2020-2034)
• Figure 22: Age group-specific Cases of PV in Japan (2020-2034)
• Figure 23: Severity-specific Cases of PV in Japan (2020-2034)
• Figure 24: Total Treated Cases of PV in Japan (2020-2034)
• Figure 25: Total Market Size of PV in the 7MM (2020-2034)
• Figure 26: Market Size of PV by Therapies in the 7MM (2020-2034)
• Figure 27: Total Market Size of PV in the US (2020-2034)
• Figure 28: Market Size of PV by Therapies in the United States (2020-2034)
• Figure 29: Total Market Size of PV in EU4 and the UK (2020-2034)
• Figure 30: Market Size of PV by Therapies in EU4 and the UK (2020-2034)
• Figure 31: Total Market Size of PV in Japan (2020-2034)
• Figure 32: Market Size of PV by Therapies in Japan (2020-2034)
• Figure 33: Unmet Needs

Key Highlights:

• According to the National Organization for Rare Disorders (2023), pemphigus vulgaris (PV) is a severe, rare autoimmune disorder marked by painful blisters and erosions on the skin and mucous membranes, including the mouth, throat, and sometimes genital areas. It occurs when the immune system mistakenly attacks desmogleins, proteins essential for cell adhesion in the epidermis, leading to cell separation and blister formation.
• Blisters associated with pemphigus are typically flaccid and fragile, forming mainly on areas like the scalp, face, chest, and back, and particularly within mucous membranes such as the mouth. They rupture easily, often resulting in painful, open sores that are slow to heal. Unlike pemphigoid, which affects deeper skin layers and produces firmer, more resilient blisters, pemphigus involves more superficial skin layers, resulting in delicate, easily ruptured blisters.
• In Pemphigus Vulgaris, autoantibodies specifically target desmogleins (proteins crucial for cell-to-cell adhesion) in the epidermis. This leads to the breakdown of cellular connections, resulting in the separation of skin cells (acantholysis) and subsequent blister formation.
• Diagnosing Pemphigus Vulgaris involves differentiating it from other blistering diseases, such as bullous pemphigoid or other types of pemphigus, through biopsy and antibody testing, particularly identifying anti-desmoglein antibodies.
• Treatment focuses on controlling the autoimmune activity that causes blistering, primarily through corticosteroids, immunosuppressants like azathioprine or mycophenolate, and biologic therapy with Rituximab, which targets B-cells responsible for autoantibody production. Currently, RITUXAN (rituximab) is the only FDA-approved therapy for the treatment of pemphigus vulgaris; it has become an effective option for achieving remission, especially in moderate-to-severe cases, often allowing for lower corticosteroid doses.
• Additional supportive treatments include antibiotics for infection prevention, pain management for oral lesions, and proper wound care to aid healing. Despite a tendency for relapse, close monitoring and these therapies help many patients manage PV, and new-targeted treatments are under investigation to improve outcomes further.
• CABA-201, a CD19-CAR T therapy developed by Cabaletta Bio, is in Phase I/II development for treating PV.
• In 2023, the United States accounted for the highest diagnosed prevalent cases of Pemphigus Vulgaris followed by Germany.
• In the 7MM, Females reported more cases than males for Pemphigus Vulgaris.
• In the United States, individuals of the 60-69 year age group reported the highest number of pemphigus Vulgaris cases.

Report Summary

• The report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.
• Additionally, an all-inclusive account of the current management techniques and emerging therapies and the elaborative profiles of late-stage (Phase III and Phase II) and prominent therapies that would impact the current treatment landscape and result in an overall market shift has been provided in the report.
• The report also encompasses a comprehensive analysis of the PV market, providing an in-depth examination of its historical and projected market size (2020-2034). It also includes the market share of therapies, detailed assumptions, and the underlying rationale for our methodology. The report also includes drug outreach coverage in the 7MM region.
• The report includes qualitative insights that provide an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey, and treatment preferences that help shape and drive the 7MM PV market.

Market

A few key players are leading the treatment landscape of Pemphigus Vulgaris, such as Roche, Cabaletta Bio, and others. The details of the country-wise and therapy-wise market size have been provided below.

• In the total market size of Pemphigus Vulgaris in the 7MM, the United States accounted for the highest market share, i.e. more than 75% in 2023, followed by Germany.
• Among EU4 and the UK, Germany accounted for almost 25% of the market size in 2023.
• The United States accounted for approximately USD 250 million in 2023.
• Among the therapies available, Rituximab appears to be the drug that has transformed the PV market.

Pemphigus Vulgaris (PV) Drug Chapters

The section dedicated to drugs in the Pemphigus Vulgaris report provides an in-depth evaluation of late-stage pipeline drugs (Phase III and Phase II) related to Pemphigus Vulgaris. The drug chapters section provides valuable information on various aspects related to clinical trials of Pemphigus Vulgaris, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases on drugs targeting Pemphigus Vulgaris.

Marketed Therapies

RITUXAN (rituximab): Roche

RITUXAN (rituximab) is the only FDA-approved therapy for the treatment of pemphigus vulgaris. It serves as a key treatment, especially for moderate to severe cases. As the first biologic therapy approved by the FDA for this condition, RITUXAN represents a significant advancement in over 60 years. The FDA has granted RITUXAN several important designations, including Priority Review, Breakthrough Therapy Designation, and Orphan Drug Designation, emphasizing its critical role in treating PV. Rituximab is a CD20-directed cytolytic antibody that targets B-cells, which are responsible for producing the autoantibodies that attack the skin and mucous membranes in PV. By depleting these B-cells, RITUXAN reduces the production of harmful antibodies, leading to improved symptoms and better disease control.

Emerging Therapies

CABA-201 (4-1BB CD19-CAR T): Cabaletta Bio

CABA-201 is designed to deeply and transiently deplete CD19-positive B cells following a one-time infusion, which may enable an "immune system reset" with the potential for durable remission of therapy in patients with autoimmune diseases. To date, Cabaletta has received clearance from the FDA for Investigational New Drug (IND) applications for CABA-201 in multiple autoimmune conditions, including Systemic Lupus Erythematosus (SLE), myositis, systemic sclerosis and generalized Myasthenia Gravis (gMG). Cabaletta is conducting four RESET Phase I/II clinical trials with a total of nine cohorts that can advance simultaneously, employing a similar parallel cohort design and starting dose of 1 x 106 cells/kg without a dose escalation requirement. In January 2020, Cabaletta Bio announced that the US Food and Drug Administration (FDA) had granted an Orphan Drug Designation for the Company's lead product candidate, DSG3-CAART, for the treatment of pemphigus vulgaris.

Pemphigus Vulgaris (PV) Market Outlook

Currently, RITUXAN (rituximab) is the only FDA-approved therapy for the treatment of pemphigus vulgaris (PV). It serves as a key treatment, especially for moderate to severe cases. As the first biologic therapy approved by the FDA for this condition, RITUXAN represents a significant advancement in over 60 years.

A CD19-CAR T-cell therapy is being developed by Cabaletta Bio for treating autoimmune diseases, including PV. Currently, in mid-stage development, CABA-201 is designed to deeply and transiently deplete CD19-positive B cells following a one-time infusion, potentially enabling an "immune system reset" and durable disease remission. Cabaletta has received FDA clearance for Investigational New Drug (IND) applications for CABA-201 in several autoimmune conditions, and the therapy is being tested in multiple RESET Phase I/II clinical trials.

In a nutshell, not many potential therapies are being investigated to manage Pemphigus Vulgaris. Even though it is too soon to comment on the above-mentioned promising candidate to enter the market during the forecast period (2024-2034). Eventually, this drug will create a significant difference in the landscape of PV in the coming years. The treatment space is expected to experience a significant positive shift in the coming years owing to the improvement in healthcare spending worldwide.

Pemphigus Vulgaris (PV) Disease Understanding and Treatment

Pemphigus Vulgaris (PV) Overview

Pemphigus is a rare autoimmune blistering disorder that affects the outermost layer of the skin (epidermis) and mucous membranes. It is characterized by the formation of fragile blisters and lesions that rupture easily, leaving painful sores. This condition arises when the immune system mistakenly produces autoantibodies-particularly against proteins called desmoglein 1 and desmoglein 3, which are essential for maintaining the adhesion between skin cells. The disruption of these cellular junctions leads to a loss of skin integrity, causing the skin cells to separate, a process known as acantholysis. As a result, fluid accumulates between the skin layers, leading to the formation of blisters.

Pemphigus Vulgaris (PV) Diagnosis

The current diagnosis of PV involves a combination of clinical assessment, histopathological examination, and advanced immunological techniques such as direct and indirect immunofluorescence and ELISA. The diagnosis of PV should be suspected in any patient with mucocutaneous erosions or blisters. The oral mucosa is the first site of involvement in the majority of cases, and PV may remain confined to the mucosal surfaces or extend to involve the skin (average lag period of 4 months).

Pemphigus Vulgaris (PV) Treatment

The treatment of Pemphigus Vulgaris has significantly improved with the use of systemic corticosteroids, which reduced the disease's mortality rate by 60%. These steroids remain the first-line therapy, particularly for mild cases, though they require careful monitoring due to side effects like infections and osteoporosis. For moderate-to-severe PV, rituximab, an anti-CD20 monoclonal antibody, is commonly used in combination with corticosteroids, helping to deplete B-cells responsible for producing the autoantibodies that attack the skin. Steroid-sparing agents like azathioprine and mycophenolate mofetil (MMF) are also used to reduce steroid dependence and minimize side effects. For refractory cases, treatments such as IVIg and cyclophosphamide may be considered. While these therapies have improved outcomes, PV treatment remains complex, requiring ongoing management to balance efficacy and side effects.

Pemphigus Vulgaris (PV) Epidemiology

The Pemphigus Vulgaris epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases, Gender-specific cases, Age-specific cases, Severity-specific cases, and total treated cases of Pemphigus Vulgaris in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2020 to 2034.

• Among the 7MM, the United States accounted for the highest number of cases of PV in 2023, with nearly 40,000 cases. These cases are anticipated to increase by 2034.
• In the United States, individuals of the 60-69 year age group account for the highest number of cases of PV in 2023.
• In the 7MM, the prevalence of females is more than males in Pemphigus Vulgaris.
• Among EU4 and the UK, Germany accounted for the highest number of diagnosed prevalent cases in 2023, while Spain accounted for the least.

KOL Views

To stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.

We have reached out to industry experts to gather insights on various aspects of Pemphigus Vulgaris, including the evolving treatment landscape, patients' reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.

Our team of analysts at Delveinsight connected with more than 15 KOLs across the 7MM. We contacted institutions such as the Johns Hopkins University School of Medicine, Stanford University School of Medicine, University of California, etc., among others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Pemphigus Vulgaris market, which will assist our clients in analyzing the overall epidemiology and market scenario.

We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in trials for Pemphigus Vulgaris, one of the most important primary endpoints was achieving hemolysis control, LDH normalization, etc. Based on these, the overall efficacy is evaluated.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Pemphigus Vulgaris (PV) Report Insights

• Patient Population
• Therapeutic Approaches
• Pemphigus Vulgaris Market Size and Trends
• Existing Market Opportunity

Pemphigus Vulgaris (PV) Report Key Strengths

• Eleven-year Forecast
• The 7MM Coverage
• Pemphigus Vulgaris Epidemiology Segmentation
• Key Cross Competition

Pemphigus Vulgaris (PV) Report Assessment

• Current Treatment Practices
• Reimbursements
• Market Attractiveness
• Qualitative Analysis (SWOT, Conjoint Analysis, Unmet needs)

Key Questions:

• Would there be any changes observed in the current treatment approach?
• Will there be any improvements in Pemphigus Vulgaris management recommendations?
• Would research and development advances pave the way for future tests and therapies for Pemphigus Vulgaris?
• Would the diagnostic testing space experience a significant impact and lead to a positive shift in the treatment landscape of Pemphigus Vulgaris?
• What kind of uptake will the new therapies witness in the coming years in Pemphigus Vulgaris patients?

Table of Contents

1. Key Insights

2. Report Introduction

3. PV Market Overview at a Glance

• 3.1. Market Share (%) Distribution of PV by Country in 2023 in the 7MM
• 3.2. Market Share (%) Distribution of PV by Country in 2034 in the 7MM

4. Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Signs and Symptoms
• 7.3. Etiology
• 7.4. Pathophysiology
• 7.5. Risk Factors
• 7.6. Diagnosis
• 7.7. Diagnostic Algorithm
• 7.8. Diagnostic Guidelines

8. Treatment and Management

• 8.1. Treatment Algorithms
• 8.2. Treatment Guidelines
  • 8.2.1. Updated S2K Guidelines on the Management of PV and Foliaceus Initiated by the European Academy of Dermatology and Venereology (EADV)

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Total Diagnosed Prevalent Cases of PV in the 7MM
• 9.4. Total Treated Cases of PV in the 7MM
• 9.5. The United States
  • 9.5.1 . Total Diagnosed Prevalent Cases of PV in the United States
  • 9.5.2. Gender-specific Cases of PV in the United States
  • 9.5.3. Age group-specific Cases of PV in the United States
  • 9.5.5. Severity-specific Cases of PV in the United States
  • 9.5.6. Treated Cases of PV in the United States
• 9.6. EU4 and the UK
  • 9.6.1. Total Diagnosed Prevalent Cases of PV in EU4 and the UK
  • 9.6.2. Gender-specific Cases of PV in EU4 and the UK
  • 9.6.3. Age group-specific Cases of PV in EU4 and the UK
  • 9.6.4. Severity-specific Cases of PV in EU4 and the UK
  • 9.6.5. Total Treated Cases of PV in EU4 and the UK
• 9.7. Japan Epidemiology
  • 9.7.1. Total Diagnosed Prevalent Cases of PV in Japan
  • 9.7.2. Gender-specific Cases of PV in Japan
  • 9.7.3. Age group-specific Cases of PV in Japan
  • 9.7.4. Severity-specific Cases of PV in Japan
  • 9.7.5. Treated Cases of PV in Japan

10. Patient Journey

11. Emerging Therapies

• 11.1. CABA-201 (4-1BB CD19-CAR T): Cabaletta Bio
  • 11.1.1 . Product Description
  • 11.1.2. Other Developmental Activities
  • 11.1.3. Clinical Developmental Activities
  • 11.1.4. Analyst View

12. Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Total Market Size of PV in the 7MM
• 12.4. Total Market Size of PV by Therapies in the 7MM
• 12.5. United States Market Size
  • 12.5.1. Total Market Size of PV in the United States
  • 12.5.2. Market Size of PV by Therapies in the United States
• 12.6. EU4 and the UK Market Size
  • 12.6.1. Total Market Size of PV in EU4 and the UK
  • 12.6.2. Market Size of PV by Therapies in EU4 and the UK
• 12.7. Japan Market Size
  • 12.7.1. Total Market Size of PV in Japan
  • 12.7.2. Market Size of PV by Therapies

13. KOL Views

14. SWOT Analysis

15. Unmet Needs

16. Appendix

• 16.1. Bibliography
• 16.2. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer